- Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 TrialCorinne Veyret
Department of Medical Oncology, Henri Becquerel Center, Rouen, France
Cancer 107:2535-44. 2006....
- Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×DocetaxelEva J Kantelhardt
Klinik und Poliklinik für Gynäkologie, Martin Luther Universitat, Halle Saale, Germany
BMC Cancer 11:140. 2011..High-risk node-negative patients should receive chemotherapy. Anthracycline-based regimens are accepted as a standard, the additional benefit of taxanes remains an open question...